HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freedberg, N. A. Search for Related Content PubMed PubMed Citation Articles by Freedberg, N. A.

CLINICAL STUDY: ELECTROPHYSIOLOGY

Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy

Implications for antiarrhythmic therapy and driving restrictions

^a The Care Group, Indianapolis, Indiana, USA
^b Nahum A. Freedberg’s current address: Cardiology Department, Ha’Emek Medical Center, Afula 18101, Israel

Manuscript received June 5, 2000; revised manuscript received January 23, 2001, accepted February 6, 2001.

Reprint requests and correspondence: Dr. Eric N. Prystowsky, The Care Group, 8333 Naab Road, Suite 200, Indianapolis, Indiana 46260
eprystow{at}thecaregroup.com

OBJECTIVES

The purpose of this study was to investigate whether clinical or electrophysiologic characteristics could predict initial and subsequent implantable cardioverter defibrillator (ICD) therapy.

BACKGROUND

Identification of markers to predict subsequent ICD therapy and symptoms after the first event could affect patient management.

METHODS

We analyzed baseline and follow-up data on 125 ICD patients followed for 408 ± 321 days. Medications and ICD programming were not changed after first ICD therapy.

RESULTS

Implantable cardioverter defibrillator therapy occurred in 58 patients (46%). Clinical features were as follows: mean left ventricular ejection fraction (LVEF) 29% ± 15%; coronary artery disease 84%; presenting arrhythmia with sustained monomorphic ventricular tachycardia (SMVT) in 68%. In a multivariate analysis the relative risk for ICD therapy in patients presenting with SMVT versus cardiac arrest (CA) was 2.57 (range, 1.32 to 5.01), and for patients with LVEF 25%, 1.95 (1.11 to 3.45), respectively (p < 0.05). Implantable cardioverter defibrillator therapy was not predicted by any other variable. Forty-six patients had second ICD therapy. Mean time to second ICD therapy was only 66 ± 93 days compared with 138 ± 168 days for first ICD therapy (p < 0.05). No predictor for second ICD therapy was found. Regarding symptoms, impaired consciousness during initial ICD therapy was predicted only by SMVT cycle length <250 ms at electrophysiologic testing. In contrast, symptoms were similar between first and second ICD therapy (p = 0.0001). Of note, ventricular tachycardia cycle length preceding first and second ICD therapy was similar (r = 0.76, p = 0.001).

CONCLUSIONS

First ICD therapy tends to occur in patients presenting with SMVT and LVEF 25%. Subsequent therapy occurs sooner and is unpredictable, suggesting that antiarrhythmic drug therapy should be considered after the first symptomatic ICD therapy. Symptoms during first ICD therapy predict subsequent symptoms, and patients presenting with SMVT and asymptomatic first ICD therapy are at very low risk for future syncopal ICD therapy.

Abbreviations and Acronyms   AAD = antiarrhythmic drug   AF = atrial fibrillation   CA = cardiac arrest   EPS = electrophysiologic study   ICD = implantable cardioverter defibrillator   LVEF = left ventricular ejection fraction   SMVT = sustained monomorphic ventricular tachycardia   VT = ventricular tachycardia

This article has been cited by other articles:

				M. H. Schoenfeld Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist Circulation, February 6, 2007; 115(5): 638 - 653. [Full Text] [PDF]

				G. Klein, C. Lissel, A.-C. Fuchs, A. Gardiwal, H. Oswald, M. deSousa, A. M. Pichlmaier, R. Lichtinghagen, H. Geerlings, P. Lippolt, et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. Europace, August 1, 2006; 8(8): 618 - 624. [Abstract] [Full Text] [PDF]

				A Verma, F Kilicaslan, D O Martin, S Minor, R Starling, N F Marrouche, S Almahammed, O M Wazni, S Duggal, R Zuzek, et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies Heart, February 1, 2006; 92(2): 190 - 195. [Abstract] [Full Text] [PDF]

				W. Whang, M. A. Mittleman, D. Q. Rich, P. J. Wang, J. N. Ruskin, G. H. Tofler, J. E. Muller, C. M. Albert, and for the TOVA Investigators Heart Failure and the Risk of Shocks in Patients With Implantable Cardioverter Defibrillators: Results From the Triggers Of Ventricular Arrhythmias (TOVA) Study Circulation, March 23, 2004; 109(11): 1386 - 1391. [Abstract] [Full Text] [PDF]

				A. E. Buxton The Clinical Use of Implantable Cardioverter Defibrillators: Where Are We Now? Where Should We Go? Ann Intern Med, March 18, 2003; 138(6): 512 - 514. [Full Text] [PDF]

				A. E. Buxton, K. L. Lee, G. E. Hafley, D. G. Wyse, J. D. Fisher, M. H. Lehmann, L. A. Pires, M. R. Gold, D. L. Packer, M. E. Josephson, et al. Relation of Ejection Fraction and Inducible Ventricular Tachycardia to Mode of Death in Patients With Coronary Artery Disease: An Analysis of Patients Enrolled in the Multicenter Unsustained Tachycardia Trial Circulation, November 5, 2002; 106(19): 2466 - 2472. [Abstract] [Full Text] [PDF]

				Arrhythmia Recurrence in ICD Patients: Incidence and Predictors Journal Watch Cardiology, August 17, 2001; 2001(817): 7 - 7. [Full Text]